[8-K] NOVAVAX INC Reports Material Event

Rhea-AI Filing Summary

Novavax, Inc. (NVAX) reported an update on results. The company furnished an 8-K stating it issued a press release with its financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1. This filing formally notifies the market of the availability of the company’s Third Quarter financial information.

FALSE000100069400010006942025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): November 6, 2025

NOVAVAX, INC.

(Exact name of registrant as specified in charter)

Delaware

0-26770

22-2816046

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

700 Quince Orchard Road

Gaithersburg, Maryland 20878

(Address of Principal Executive Offices, including Zip Code)

(240) 268-2000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, Par Value $0.01 per share

NVAX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

Third Quarter Financial Results

On November 6, 2025, Novavax, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description
99.1						Press release, dated November 6, 2025, regarding the Company’s financial results for the quarter ended September 30, 2025.
104						Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NOVAVAX, INC.
Date: November 6, 2025			By:			/s/ Mark J. Casey
			Name:			Mark J. Casey
			Title:			Executive Vice President, Chief Legal Officer and Corporate Secretary

FAQ

What did Novavax (NVAX) announce in this 8-K?

Novavax reported that it issued a press release with financial results for the quarter ended September 30, 2025, furnished as Exhibit 99.1.

Which period does the NVAX update cover?

It covers the company’s financial results for the quarter ended September 30, 2025.

Where can I find the detailed results for NVAX?

The detailed results are in the press release attached as Exhibit 99.1 to the 8-K.

What is the form type of this Novavax filing?

It is a Form 8-K.

What exchange lists NVAX common stock?

NVAX common stock is listed on The Nasdaq Global Select Market.

Who signed the Novavax 8-K?

Mark J. Casey, Executive Vice President, Chief Legal Officer and Corporate Secretary, signed the filing.